Isoliquiritigenin suppresses E2-induced uterine leiomyoma growth through the modulation of cell death program and the repression of ECM accumulation

Po Han Lin, Hsiang Lin Kung, Hsin Yuan Chen, Ko Chieh Huang, Shih Min Hsia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Uterine leiomyomas, also known as fibroids, are common and prevalent in women of reproductive age. In this study, the effect of Isoliquiritigenin (ISL), a licorice flavonoid, on the anti-proliferation of uterine leiomyoma was investigated. We found that the survival of uterine leiomyoma ELT3 cells and primary uterine smooth muscle (UtSMC) cells was reduced by treatment with ISL alone or with ISL plus estradiol (E2). Cell cycles were arrested through the reduction of G2/M-and S-phase populations in ELT3 and UtSMC cells, respectively. Furthermore, increased sub-G1 phase and nucleus condensation were observed in ELT3 cells but not in UtSMC cells. Co-treatment of ELT3 cells with E2 and ISL inhibited ERK1/2 activation, whereas p38 and c-Jun N-terminal kinase (JNK) activation was enhanced. Moreover, ISL-induced apoptosis and autophagy cell death in ELT3 cells were observed. Serum E2 and P4 levels were reduced in a E2-enhanced uterine myometrium hyperplasia mouse model by ISL treatment, which contributed to the downregulation of the expression of extracellular matrix (ECM) associated proteins and matrix metalloproteinase (MMPs). Taken together, these results showed that ISL exerted a higher effect on the inhibition of estrogen-induced uterine leiomyoma growth for both in vitro and in vivo ECM accumulation, demonstrating its potential as a new option for treatment of uterine leiomyoma.

Original languageEnglish
Article number1131
JournalCancers
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Leiomyoma
Extracellular Matrix
Cell Death
Myometrium
Growth
Smooth Muscle Myocytes
Glycyrrhiza
JNK Mitogen-Activated Protein Kinases
Extracellular Matrix Proteins
Autophagy
G1 Phase
Therapeutics
isoliquiritigenin
Matrix Metalloproteinases
S Phase
Flavonoids
Cell Division
Hyperplasia
Estradiol
Cell Cycle

Keywords

  • Apoptosis
  • Autophagy
  • Extracellular matrix
  • Isoliquiritigenin
  • Uterine leiomyoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Isoliquiritigenin suppresses E2-induced uterine leiomyoma growth through the modulation of cell death program and the repression of ECM accumulation. / Lin, Po Han; Kung, Hsiang Lin; Chen, Hsin Yuan; Huang, Ko Chieh; Hsia, Shih Min.

In: Cancers, Vol. 11, No. 8, 1131, 01.08.2019.

Research output: Contribution to journalArticle

@article{c3371c36499d4bbea2069faae73d812d,
title = "Isoliquiritigenin suppresses E2-induced uterine leiomyoma growth through the modulation of cell death program and the repression of ECM accumulation",
abstract = "Uterine leiomyomas, also known as fibroids, are common and prevalent in women of reproductive age. In this study, the effect of Isoliquiritigenin (ISL), a licorice flavonoid, on the anti-proliferation of uterine leiomyoma was investigated. We found that the survival of uterine leiomyoma ELT3 cells and primary uterine smooth muscle (UtSMC) cells was reduced by treatment with ISL alone or with ISL plus estradiol (E2). Cell cycles were arrested through the reduction of G2/M-and S-phase populations in ELT3 and UtSMC cells, respectively. Furthermore, increased sub-G1 phase and nucleus condensation were observed in ELT3 cells but not in UtSMC cells. Co-treatment of ELT3 cells with E2 and ISL inhibited ERK1/2 activation, whereas p38 and c-Jun N-terminal kinase (JNK) activation was enhanced. Moreover, ISL-induced apoptosis and autophagy cell death in ELT3 cells were observed. Serum E2 and P4 levels were reduced in a E2-enhanced uterine myometrium hyperplasia mouse model by ISL treatment, which contributed to the downregulation of the expression of extracellular matrix (ECM) associated proteins and matrix metalloproteinase (MMPs). Taken together, these results showed that ISL exerted a higher effect on the inhibition of estrogen-induced uterine leiomyoma growth for both in vitro and in vivo ECM accumulation, demonstrating its potential as a new option for treatment of uterine leiomyoma.",
keywords = "Apoptosis, Autophagy, Extracellular matrix, Isoliquiritigenin, Uterine leiomyoma",
author = "Lin, {Po Han} and Kung, {Hsiang Lin} and Chen, {Hsin Yuan} and Huang, {Ko Chieh} and Hsia, {Shih Min}",
year = "2019",
month = "8",
day = "1",
doi = "10.3390/cancers11081131",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Isoliquiritigenin suppresses E2-induced uterine leiomyoma growth through the modulation of cell death program and the repression of ECM accumulation

AU - Lin, Po Han

AU - Kung, Hsiang Lin

AU - Chen, Hsin Yuan

AU - Huang, Ko Chieh

AU - Hsia, Shih Min

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Uterine leiomyomas, also known as fibroids, are common and prevalent in women of reproductive age. In this study, the effect of Isoliquiritigenin (ISL), a licorice flavonoid, on the anti-proliferation of uterine leiomyoma was investigated. We found that the survival of uterine leiomyoma ELT3 cells and primary uterine smooth muscle (UtSMC) cells was reduced by treatment with ISL alone or with ISL plus estradiol (E2). Cell cycles were arrested through the reduction of G2/M-and S-phase populations in ELT3 and UtSMC cells, respectively. Furthermore, increased sub-G1 phase and nucleus condensation were observed in ELT3 cells but not in UtSMC cells. Co-treatment of ELT3 cells with E2 and ISL inhibited ERK1/2 activation, whereas p38 and c-Jun N-terminal kinase (JNK) activation was enhanced. Moreover, ISL-induced apoptosis and autophagy cell death in ELT3 cells were observed. Serum E2 and P4 levels were reduced in a E2-enhanced uterine myometrium hyperplasia mouse model by ISL treatment, which contributed to the downregulation of the expression of extracellular matrix (ECM) associated proteins and matrix metalloproteinase (MMPs). Taken together, these results showed that ISL exerted a higher effect on the inhibition of estrogen-induced uterine leiomyoma growth for both in vitro and in vivo ECM accumulation, demonstrating its potential as a new option for treatment of uterine leiomyoma.

AB - Uterine leiomyomas, also known as fibroids, are common and prevalent in women of reproductive age. In this study, the effect of Isoliquiritigenin (ISL), a licorice flavonoid, on the anti-proliferation of uterine leiomyoma was investigated. We found that the survival of uterine leiomyoma ELT3 cells and primary uterine smooth muscle (UtSMC) cells was reduced by treatment with ISL alone or with ISL plus estradiol (E2). Cell cycles were arrested through the reduction of G2/M-and S-phase populations in ELT3 and UtSMC cells, respectively. Furthermore, increased sub-G1 phase and nucleus condensation were observed in ELT3 cells but not in UtSMC cells. Co-treatment of ELT3 cells with E2 and ISL inhibited ERK1/2 activation, whereas p38 and c-Jun N-terminal kinase (JNK) activation was enhanced. Moreover, ISL-induced apoptosis and autophagy cell death in ELT3 cells were observed. Serum E2 and P4 levels were reduced in a E2-enhanced uterine myometrium hyperplasia mouse model by ISL treatment, which contributed to the downregulation of the expression of extracellular matrix (ECM) associated proteins and matrix metalloproteinase (MMPs). Taken together, these results showed that ISL exerted a higher effect on the inhibition of estrogen-induced uterine leiomyoma growth for both in vitro and in vivo ECM accumulation, demonstrating its potential as a new option for treatment of uterine leiomyoma.

KW - Apoptosis

KW - Autophagy

KW - Extracellular matrix

KW - Isoliquiritigenin

KW - Uterine leiomyoma

UR - http://www.scopus.com/inward/record.url?scp=85071195784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071195784&partnerID=8YFLogxK

U2 - 10.3390/cancers11081131

DO - 10.3390/cancers11081131

M3 - Article

AN - SCOPUS:85071195784

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 8

M1 - 1131

ER -